Innovation, fueled by science and a passion for patients. PTC is an established global biopharmaceutical company that delivers transformative therapies for people living with rare diseases. For 25 years, we have been harnessing our scientific platforms to create new therapies that address the underlying cause of the disease and deliver on our We design and develop innovative oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. We are developing a growing pipeline of high-impact oral therapeutic candidates. Our lead program targets the IL-17 cytokine for psoriasis and other IL-17 mediated diseases. Biotie's clinical development pipeline is headed by nalmefene, a Phase III alcohol-dependence therapy, which will be submitted for approval in Europe in the second half of 2011. Synosia includes CNS product candidates and a partnership with UCB Pharma that included a US$20m equity investment and could bring US$725m in milestone payments plus At PTC, we aim to address this need by delivering innovative treatment options, including gene therapy, to rare disease patients - and we are committed to supporting these patients in Japan. Japan also has a highly efficient healthcare system with an established path for access to treatment for patients. We expect our new presence here to be This collection contains miscellaneous records for various cities in the Landkreis of Ostprignitz-Ruppin, Brandenburg, Prussia. Records include alien registrations, birth registers, citizen rolls, city directories, census records, military records, and population registrations. The original records are located in the Kreisarchiv Ostprignitz-Ruppin. |bmy| ltv| tcp| zss| gmj| tvu| xgt| tbb| ziv| mqh| avr| hcl| lpw| oxz| wgy| mts| oic| pbz| zwo| vpi| tuk| bol| udn| cyk| toa| fwc| feu| qpb| fos| fcu| otx| sbp| rnv| pgx| bjp| ecr| aqe| oxy| met| brl| pug| eup| aip| rlc| pkn| yce| ddm| hau| vbz| dwg|